Bank Of New York Mellon Corp Annexon, Inc. Transaction History

Bank Of New York Mellon Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$3.74 - $7.46 $140,874 - $280,995	37,667 New	37,667 $145 Million
Q4 2022 Feb 14, 2023	BUY	$4.56 - $6.61 $171,761 - $248,978	37,667 New	37,667 $194,000
Q3 2022 Nov 14, 2022	BUY	$3.75 - $6.63 $66,251 - $117,132	17,667 New	17,667 $109,000
Q2 2022 Aug 15, 2022	SELL	$2.11 - $4.06 $208,976 - $402,106	-99,041 Closed	0 $0
Q1 2022 May 11, 2022	SELL	$2.73 - $11.94 $6,112 - $26,733	-2,239 Reduced 2.21%	99,041 $270,000
Q4 2021 Feb 11, 2022	SELL	$11.49 - $22.0 $23,968 - $45,892	-2,086 Reduced 2.02%	101,280 $1.16 Million
Q3 2021 Nov 12, 2021	BUY	$16.35 - $23.4 $146,839 - $210,155	8,981 Added 9.52%	103,366 $1.92 Million
Q2 2021 Aug 11, 2021	BUY	$17.81 - $27.48 $283,446 - $437,344	15,915 Added 20.28%	94,385 $2.12 Million
Q1 2021 May 13, 2021	BUY	$22.0 - $35.01 $400,158 - $636,796	18,189 Added 30.17%	78,470 $2.18 Million
Q4 2020 Feb 09, 2021	BUY	$20.81 - $30.55 $481,356 - $706,652	23,131 Added 62.26%	60,281 $1.51 Million
Q3 2020 Nov 12, 2020	BUY	$17.5 - $30.23 $650,125 - $1.12 Million	37,150 New	37,150 $1.12 Million

158

102M

3.61M

1.08M

Ticker ANNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,617,700
Market Cap $312M
Description
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.